PubMed HealthSearch

Biomedical subjects

A Urayama

Publications and source records attributed to A Urayama.

14 recordsLinked to original sources

A nationwide survey on the occurrence of Vogt-Koyanagi-Harada disease in Japan.

A nationwide survey was carried out to estimate the frequency and distribution of Vogt-Koyanagi-Harada disease in Japan. A questionnaire was mailed to the Departments of Ophthalmology in hospitals with 200 or more beds. Responses were received from 489 out of 1,077 institutions, or 45.5%. The annual prevalence was estimated to be 15.5 per million and the incidence was 6.5 per million, based on the number of reported cases and the response rate per prefecture. It was estimated that 1,800 patients were treated for this disease annually and that there were about 800 new cases each year. Geographical distribution showed no special characteristics such as those seen with Behçet's disease. The results of the analysis of 1,833 reported cases showed that females were slightly more often affected than males. For both male and female patients, the age distribution on the first visit showed a peak in the fifth decade and a median age of 42.3 years.

Adolescent

[A nation-wide survey on the occurrence of Vogt-Koyanagi-Harada disease in Japan].

A nation-wide survey was performed to estimate the frequency and distribution of Vogt-Koyanagi-Harada's disease (Harada's disease hereinafter). A questionnaire was mailed to the departments of ophthalmology in hospitals with at least 200 beds. The response rate was 489 out of 1,077 institutions, or 45.4%. The annual prevalence was estimated to be 15.5 per million and the incidence was 6.5 per million, based on the number of reported cases and the response rate per prefecture. It was estimated that 1,800 patients were treated for this disease annually and that there were about 800 new cases. Geographical distribution showed no special characteristics such as these seen with Behçet's disease. The results of the analysis of 1,833 cases showed that females were slightly more affected than males, with an age distribution on first visit which showed a peak in the fourth decade and with the median age being 42.3 years.

Adolescent

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.

The efficacy and safety of oral cyclosporin 10 mg/kg per day in Behçet's disease were compared in a randomised double-masked study with those of colchicine, 1 mg orally per day, and were also investigated in a long-term open study. The double-masked study showed that cyclosporin was effective in treating not only the ocular manifestations of Behçet's disease but also oral aphthous ulcer, dermal lesions, and genital ulceration. Efficacy did not weaken during long-term treatment.

Administration, Oral